「ceoメッセージ」の検索結果
69件：41～45件目を表示
-
お知らせ | 千寿製薬株式会社
August 20, 2026 Senju initiated Phase III Clinical Trials in Japan for "SJP-0049" for the treatment of Allergic Conjunctivitis（PDF） June 1, 2026 Launch of Distribution of 3in1Smart and SPM-7
https://www.senju.co.jp/english/news/ -
NewMytear A | OTC Products, etc. | Products | SENJU Pharmaceutical
Category 3 OTC medicines New Mytear® A Supplies moisture. CHARACTERISTICS This is an artificial tear-type eye drop with mild sensation. It supplies the moisture of tears that is important to the eyes
https://www.senju.co.jp/english/products/myteara.html -
Animal Science | Business Activities | About Senju | SENJU Pharmaceutical
Evolving into a Senses-Enhancing Enterprise with a Consummate Pet-related Product Line Pets are our precious companions. They have the right to enjoy the same comforts we do. Through the development o
https://www.senju.co.jp/english/about/business/animal.html -
Quality Policies | About Senju | SENJU Pharmaceutical
We will set the following "Quality Policies" and continue to be a "Good Company" by encouraging cooperation among all employees and providing high-quality products for "realiz
https://www.senju.co.jp/english/about/quality.html -
Business Activities | About Senju | SENJU Pharmaceutical
Based on a sense of mission to contribute to the health of the eyes of people around the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in oph
https://www.senju.co.jp/english/about/business/